Tier 4 — mechanistic

Potential pharmacological effect of Quercetin Phytosome™ in the management of hyperuricemia: results from real-life clinical studies

Francesco Di Pierro, Fazle Rabbani, Meherullah Tareen, Roohi Nigar, Amjad Khan, Nicola Zerbinati, Maria L Tanda, Massimiliano Cazzaniga, Alexander Bertuccioli, Paolo Falasca, Gabriele Damiani, Nicola Villanova
Frontiers in nutrition 2025 12:1519459

Bibliography

PubMed
PMID 39990611
PubMed Central
PMC11844220
DOI
10.3389/fnut.2025.1519459
Funding
Funding was not specified in the indexed record or the disclosure metadata available for this entry.
Competing interests
Reported disclosure: FD belongs to the Scientific Board of Pharmextracta. MC and AB are Pharmextracta consultants. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Study snapshot

DesignRetrospective analysis of three real-world clinical cohorts
ModelHuman observational research
Sample164, 22, and 64 participants in three distinct cohorts
InterventionQuercetin Phytosome providing 400 mg quercetin/day; different comparator regimens across cohorts
DurationCohort-dependent follow-up; 90 days in the first cohort
EndpointsLipid measurements; Uric acid

What the study showed, in plain terms

Published in 2025, this source examined uric acid and gout. Design: Retrospective analysis of three real-world clinical cohorts. Sample/model: 164, 22, and 64 participants in three distinct cohorts. The exposure or intervention was Quercetin Phytosome providing 400 mg quercetin/day; different comparator regimens across cohorts. Follow-up or treatment period: Cohort-dependent follow-up; 90 days in the first cohort.

Uric acid decreased in the quercetin-treated groups, with some triglyceride changes.

Nonrandomized cohorts, differing comparators, formulation-specific exposure, and possible confounding limit causal inference. It does not establish prevention of gout attacks.

Continue with Quercetin Data Center

For topic-level interpretation, read Quercetin for Uric Acid and Gout: What the Trial Shows. This is a related guide; the citation panel separately identifies articles that directly cite this paper.

Key findings

  • Uric acid decreased in the quercetin-treated groups, with some triglyceride changes.
  • The recorded outcome domains were Lipid measurements; Uric acid.
  • The exposure was observed rather than assigned as an isolated supplement treatment.

What this study can and cannot tell us

  • Nonrandomized cohorts, differing comparators, formulation-specific exposure, and possible confounding limit causal inference. It does not establish prevention of gout attacks.
  • Confounding, dietary patterns, illness, medication use and reverse causation can influence an association. Blood or dietary concentrations do not identify the effect of starting a capsule.
  • Source basis: Source check: PubMed abstract and indexed metadata; full methods were not independently confirmed for this entry. Missing method details, funding information or participant denominators are not inferred.

Citation network

Articles citing this research paper

1 article

Biohack Blueprint analyses that reference this study in their evidence base.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology